Quick Takeaways
- American Endowment Foundation filed SCHEDULE 13G/A for Cyclerion Therapeutics Inc. Common Stock, no par value (CYCN).
- Disclosed ownership: 4.9%.
- Date of event: 31 Dec 2024.
American Endowment Foundation - 31 Dec 2024 SCHEDULE 13G/A Report for Cyclerion Therapeutics Inc. Common Stock, no par value (CYCN)
- Filing Manager
- American Endowment Foundation
- Reporting Manager
- American Endowment Foundation
- Symbol
- CYCN
- Shares outstanding
- 2,709,287 shares
- Disclosed Ownership
- 133,026 shares
- Ownership
- 4.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 12 Feb 2025, 13:25:51 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"American Endowment Foundation disclosed 4.9% ownership in Cyclerion Therapeutics Inc. Common Stock, no par value (CYCN) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 12 Feb 2025, 13:25.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| American Endowment Foundation | 4.9% | 133,026 | 0 | 133,026 | /s/ Michele L. Hoza | Michele L. Hoza, General Counsel |